February 2003

Table 1: Propellants used in medical metered dose inhalers and aerosol-based breath activated devices in New Zealand August to October 2002 (most recent period for which data is available)

	Inhalers containing CFCs	CFC-free inhalers
Unit volumes during time period (millions of doses)
Salbutamol inhalers	4.9	67.4
Total inhaled short acting beta agonists and anticholinergic reliever inhalers	18.8	67.4
Total inhaled corticosteroid inhalers	18.0	23.8
Total inhaled long acting beta agonist inhalers	5.5	0.0
Total unit volumes	42.3	91.2
Proportion of market
Salbutamol inhalers	7%	93%
Total inhaled short acting beta agonists and anticholinergic reliever inhalers	22%	78%
Total inhaled corticosteroid inhalers	43%	57%
Total inhaled long acting beta agonist inhalers	100%	0%
Total	32%	68%